Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dyne Therapeutics, Inc.DYN · Entity 3948 | Director | July 27, 2026 | July 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dyne Therapeutics, Inc.
Report date July 27, 2026 · Filed July 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 3,586,796 |
Last balance in matching sequence
After 2026-07-27 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-07-27 · Sale · Disposed 256,072 · Balance 3,592,184 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. ("ForDyne") on November 11, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.995, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F3: The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") and Forbion Growth Opportunities Fund II Cooperatief U.A. ("FGO II"). Forbion IV Management B.V. ("Forbion Management") may be deemed to have voting and dispositive power over 2,160,426 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. F4: (Continued from Footnote 3) Forbion Growth II Management B.V. ("FGO II Management"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Row 2 · 2026-07-27 · Sale · Disposed 5,388 · Balance 3,586,796 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. ("ForDyne") on November 11, 2025. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.00 to $26.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F3: The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") and Forbion Growth Opportunities Fund II Cooperatief U.A. ("FGO II"). Forbion IV Management B.V. ("Forbion Management") may be deemed to have voting and dispositive power over 2,160,426 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. F4: (Continued from Footnote 3) Forbion Growth II Management B.V. ("FGO II Management"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. ("ForDyne") on November 11, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.995, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4.
F3: The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") and Forbion Growth Opportunities Fund II Cooperatief U.A. ("FGO II"). Forbion IV Management B.V. ("Forbion Management") may be deemed to have voting and dispositive power over 2,160,426 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.
F4: (Continued from Footnote 3) Forbion Growth II Management B.V. ("FGO II Management"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.00 to $26.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 27, 2026 Filed Jul 29, 2026 20:15 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 5,388 | $26.04 | $140,318.61 |
DisclosureSEC source: 0001193125-26-323754 · ownership.xml · nonDerivative · entry 2 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 3,586,796 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. ("ForDyne") on November 11, 2025. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.00 to $26.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F3 · ownership.nature: The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") and Forbion Growth Opportunities Fund II Cooperatief U.A. ("FGO II"). Forbion IV Management B.V. ("Forbion Management") may be deemed to have voting and dispositive power over 2,160,426 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. F4 · ownership.nature: (Continued from Footnote 3) Forbion Growth II Management B.V. ("FGO II Management"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| July 27, 2026 Filed Jul 29, 2026 20:15 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 256,072 | $25.50 | $6,530,450.57 |
DisclosureSEC source: 0001193125-26-323754 · ownership.xml · nonDerivative · entry 1 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 3,592,184 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. ("ForDyne") on November 11, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.995, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F3 · ownership.nature: The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") and Forbion Growth Opportunities Fund II Cooperatief U.A. ("FGO II"). Forbion IV Management B.V. ("Forbion Management") may be deemed to have voting and dispositive power over 2,160,426 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. F4 · ownership.nature: (Continued from Footnote 3) Forbion Growth II Management B.V. ("FGO II Management"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| June 23, 2026 Filed Jun 24, 2026 20:27 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,657 | $21.47 | $35,582.75 |
DisclosureSEC source: 0001193125-26-281119 · ownership.xml · nonDerivative · entry 3 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 3,848,256 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. ("ForDyne") on November 11, 2025. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $21.45 to $21.495, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F3 · ownership.nature: The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") and Forbion Growth Opportunities Fund II Cooperatief U.A. ("FGO II"). Forbion IV Management B.V. ("Forbion Management") may be deemed to have voting and dispositive power over 2,421,886 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. F4 · ownership.nature: (Continued from Footnote 2) Forbion Growth II Management B.V. ("FGO II Management"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| June 23, 2026 Filed Jun 24, 2026 20:27 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 71,629 | $21.04 | $1,506,766.16 |
DisclosureSEC source: 0001193125-26-281119 · ownership.xml · nonDerivative · entry 2 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 3,849,913 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. ("ForDyne") on November 11, 2025. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.45 to $21.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F3 · ownership.nature: The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") and Forbion Growth Opportunities Fund II Cooperatief U.A. ("FGO II"). Forbion IV Management B.V. ("Forbion Management") may be deemed to have voting and dispositive power over 2,421,886 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. F4 · ownership.nature: (Continued from Footnote 2) Forbion Growth II Management B.V. ("FGO II Management"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 20:27 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 190,676 | $20.57 | $3,922,262.52 |
DisclosureSEC source: 0001193125-26-281119 · ownership.xml · nonDerivative · entry 1 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 3,921,542 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. ("ForDyne") on November 11, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.13 to $20.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F3 · ownership.nature: The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") and Forbion Growth Opportunities Fund II Cooperatief U.A. ("FGO II"). Forbion IV Management B.V. ("Forbion Management") may be deemed to have voting and dispositive power over 2,421,886 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. F4 · ownership.nature: (Continued from Footnote 2) Forbion Growth II Management B.V. ("FGO II Management"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| June 18, 2026 Filed Jun 22, 2026 20:15 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 46,901 | $20.07 | $941,373.42 |
DisclosureSEC source: 0001193125-26-277529 · ownership.xml · nonDerivative · entry 2 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 4,112,218 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. ("ForDyne") on November 11, 2025. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.00 to $20.485, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F3 · ownership.nature: The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") and Forbion Growth Opportunities Fund II Cooperatief U.A. ("FGO II"). Forbion IV Management B.V. ("Forbion Management") may be deemed to have voting and dispositive power over 2,685,848 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. F4 · ownership.nature: (Continued from Footnote 2) Forbion Growth II Management B.V. ("FGO II Management"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:15 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 37,454 | $20.14 | $754,316.07 |
DisclosureSEC source: 0001193125-26-277529 · ownership.xml · nonDerivative · entry 1 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 4,159,119 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. ("ForDyne") on November 11, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.00 to $20.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F3 · ownership.nature: The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") and Forbion Growth Opportunities Fund II Cooperatief U.A. ("FGO II"). Forbion IV Management B.V. ("Forbion Management") may be deemed to have voting and dispositive power over 2,685,848 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. F4 · ownership.nature: (Continued from Footnote 2) Forbion Growth II Management B.V. ("FGO II Management"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 21:12 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock option (right to buy) · Derivative | 35,152 | $0.00 Strike: $17.04 | $0.00 |
DisclosureSEC source: 0001193125-26-264021 · ownership.xml · derivative · entry 1 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,152 Underlying: Common Stock · 35,152 shares Expires 2036-06-04 F1 · derivative.exercise_date: This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service. Read SEC document |
| April 22, 2026 Filed Apr 23, 2026 20:15 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 2,652 | $20.00 | $53,049.28 |
DisclosureSEC source: 0001193125-26-173736 · ownership.xml · nonDerivative · entry 2 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 4,196,573 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. ("ForDyne") on November 11, 2025. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.00 to $20.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F3 · ownership.nature: The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") and Forbion Growth Opportunities Fund II Cooperatief U.A. ("FGO II"). Forbion IV Management B.V. ("Forbion Management") may be deemed to have voting and dispositive power over 2,770,203 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. F4 · ownership.nature: (Continued) Forbion Growth II Management B.V. ("FGO II Management"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| April 21, 2026 Filed Apr 23, 2026 20:15 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 8,300 | $20.01 | $166,120.35 |
DisclosureSEC source: 0001193125-26-173736 · ownership.xml · nonDerivative · entry 1 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 4,199,225 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. ("ForDyne") on November 11, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.00 to $20.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F3 · ownership.nature: The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") and Forbion Growth Opportunities Fund II Cooperatief U.A. ("FGO II"). Forbion IV Management B.V. ("Forbion Management") may be deemed to have voting and dispositive power over 2,770,203 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. F4 · ownership.nature: (Continued) Forbion Growth II Management B.V. ("FGO II Management"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 20:15 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 125,274 | $20.07 | $2,513,898.41 |
DisclosureSEC source: 0001193125-26-166822 · ownership.xml · nonDerivative · entry 2 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 4,207,525 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. ("ForDyne") on November 11, 2025. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $21.00 to $21.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F3 · ownership.nature: The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") and Forbion Growth Opportunities Fund II Cooperatief U.A. ("FGO II"). Forbion IV Management B.V. ("Forbion Management") may be deemed to have voting and dispositive power over 2,781,155 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. F4 · ownership.nature: (Continued from Footnote 2) Forbion Growth II Management B.V. ("FGO II Management"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| April 17, 2026 Filed Apr 21, 2026 20:15 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 211,974 | $20.29 | $4,301,291.62 |
DisclosureSEC source: 0001193125-26-166822 · ownership.xml · nonDerivative · entry 1 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 4,332,799 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. ("ForDyne") on November 11, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.00 to $20.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F3 · ownership.nature: The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") and Forbion Growth Opportunities Fund II Cooperatief U.A. ("FGO II"). Forbion IV Management B.V. ("Forbion Management") may be deemed to have voting and dispositive power over 2,781,155 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. F4 · ownership.nature: (Continued from Footnote 2) Forbion Growth II Management B.V. ("FGO II Management"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| April 16, 2026 Filed Apr 17, 2026 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 6,657 | $20.06 | $133,522.78 |
DisclosureSEC source: 0001193125-26-161508 · ownership.xml · nonDerivative · entry 3 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 4,544,773 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. ("ForDyne") on November 11, 2025. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.00 to $20.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F3 · ownership.nature: The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") and Forbion Growth Opportunities Fund II Cooperatief U.A. ("FGO II"). Forbion IV Management B.V. ("Forbion Management") may be deemed to have voting and dispositive power over 3,118,403 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. F4 · ownership.nature: (Continued from Footnote 2) Forbion Growth II Management B.V. ("FGO II Management"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| April 16, 2026 Filed Apr 17, 2026 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 11,116 | $21.10 | $234,590.95 |
DisclosureSEC source: 0001193125-26-161508 · ownership.xml · nonDerivative · entry 2 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 4,551,430 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. ("ForDyne") on November 11, 2025. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $21.00 to $21.345, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F3 · ownership.nature: The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") and Forbion Growth Opportunities Fund II Cooperatief U.A. ("FGO II"). Forbion IV Management B.V. ("Forbion Management") may be deemed to have voting and dispositive power over 3,118,403 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. F4 · ownership.nature: (Continued from Footnote 2) Forbion Growth II Management B.V. ("FGO II Management"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 81,840 | $20.27 | $1,659,044.11 |
DisclosureSEC source: 0001193125-26-161508 · ownership.xml · nonDerivative · entry 1 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 4,562,546 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. ("ForDyne") on November 11, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.00 to $20.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F3 · ownership.nature: The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") and Forbion Growth Opportunities Fund II Cooperatief U.A. ("FGO II"). Forbion IV Management B.V. ("Forbion Management") may be deemed to have voting and dispositive power over 3,118,403 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. F4 · ownership.nature: (Continued from Footnote 2) Forbion Growth II Management B.V. ("FGO II Management"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| March 11, 2026 Filed Mar 13, 2026 20:35 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 129,672 | $19.52 | $2,530,562.05 |
DisclosureSEC source: 0001193125-26-106269 · ownership.xml · nonDerivative · entry 1 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 4,644,386 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. ("ForDyne") on November 11, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.88 to $19.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F3 · ownership.nature: The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") and Forbion Growth Opportunities Fund II Cooperatief U.A. ("FGO II"). Forbion IV Management B.V. ("Forbion Management") may be deemed to have voting and dispositive power over 3,218,016 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. F4 · ownership.nature: (Continued from Footnote 2) Forbion Growth II Management B.V. ("FGO II Management"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 21:27 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 281,858 | $19.80 | $5,580,816.59 |
DisclosureSEC source: 0001193125-26-102469 · ownership.xml · nonDerivative · entry 4 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 4,774,058 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. ("ForDyne") on November 11, 2025. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $19.61 to $20.03, inclusive. F3 · ownership.nature: The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") and Forbion Growth Opportunities Fund II Cooperatief U.A. ("FGO II"). Forbion IV Management B.V. ("Forbion Management") may be deemed to have voting and dispositive power over 3,347,688 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. F4 · ownership.nature: (Continued from Footnote 2) Forbion Growth II Management B.V. ("FGO II Management"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 21:27 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 219,758 | $19.33 | $4,246,823.35 |
DisclosureSEC source: 0001193125-26-102469 · ownership.xml · nonDerivative · entry 3 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 5,055,916 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. ("ForDyne") on November 11, 2025. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.61 to $19.605, inclusive. F3 · ownership.nature: The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") and Forbion Growth Opportunities Fund II Cooperatief U.A. ("FGO II"). Forbion IV Management B.V. ("Forbion Management") may be deemed to have voting and dispositive power over 3,347,688 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. F4 · ownership.nature: (Continued from Footnote 2) Forbion Growth II Management B.V. ("FGO II Management"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 21:27 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 9,482 | $18.21 | $172,687.13 |
DisclosureSEC source: 0001193125-26-102469 · ownership.xml · nonDerivative · entry 2 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 5,275,674 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. ("ForDyne") on November 11, 2025. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $17.595 to $18.59, inclusive. F3 · ownership.nature: The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") and Forbion Growth Opportunities Fund II Cooperatief U.A. ("FGO II"). Forbion IV Management B.V. ("Forbion Management") may be deemed to have voting and dispositive power over 3,347,688 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. F4 · ownership.nature: (Continued from Footnote 2) Forbion Growth II Management B.V. ("FGO II Management"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 21:27 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 177,690 | $17.72 | $3,148,986.64 |
DisclosureSEC source: 0001193125-26-102469 · ownership.xml · nonDerivative · entry 1 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 5,285,156 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. ("ForDyne") on November 11, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $17.50 to $18.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F3 · ownership.nature: The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") and Forbion Growth Opportunities Fund II Cooperatief U.A. ("FGO II"). Forbion IV Management B.V. ("Forbion Management") may be deemed to have voting and dispositive power over 3,347,688 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. F4 · ownership.nature: (Continued from Footnote 2) Forbion Growth II Management B.V. ("FGO II Management"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| May 30, 2025 Filed Jun 4, 2025 01:38 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock option (right to buy) · Derivative | 35,000 | $0.00 Strike: $11.96 | $0.00 |
DisclosureSEC source: 0000950170-25-081355 · ownership.xml · derivative · entry 1 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2035-05-29 F1 · derivative.exercise_date: This option was granted on May 30, 2025. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 30, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 21:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 34,437 | $29.18 | $1,004,871.66 |
DisclosureSEC source: 0000950170-24-134961 · ownership.xml · nonDerivative · entry 2 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 5,400,545 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $29.00 to $29.66, inclusive. F2 · ownership.nature: The shares are held directly by ForDyne B.V. ("ForDyne"). ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") and Forbion Growth Opportunities Fund II Cooperatief U.A. ("FGO II"). Forbion IV Management B.V. ("Forbion Management") may be deemed to have voting and dispositive power over 3,974,175 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. F3 · ownership.nature: (Continued from Footnote 2) Forbion Growth II Management B.V. ("FGO II Management"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| December 06, 2024 Filed Dec 10, 2024 21:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 101,675 | $29.34 | $2,983,144.50 |
DisclosureSEC source: 0000950170-24-134961 · ownership.xml · nonDerivative · entry 1 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 5,434,982 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $29.00 to $29.565, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F2 · ownership.nature: The shares are held directly by ForDyne B.V. ("ForDyne"). ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") and Forbion Growth Opportunities Fund II Cooperatief U.A. ("FGO II"). Forbion IV Management B.V. ("Forbion Management") may be deemed to have voting and dispositive power over 3,974,175 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. F3 · ownership.nature: (Continued from Footnote 2) Forbion Growth II Management B.V. ("FGO II Management"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| December 05, 2024 Filed Dec 6, 2024 21:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 3,806 | $29.05 | $110,564.30 |
DisclosureSEC source: 0000950170-24-134076 · ownership.xml · nonDerivative · entry 2 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 5,536,657 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $29.00 to $29.365, inclusive. F2 · ownership.nature: The shares are held directly by ForDyne B.V. ("ForDyne"). ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") and Forbion Growth Opportunities Fund II Cooperatief U.A. ("FGO II"). Forbion IV Management B.V. ("Forbion Management") may be deemed to have voting and dispositive power over 4,110,287 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. F3 · ownership.nature: (Continued from Footnote 2) Forbion Growth II Management B.V. ("FGO II Management"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| December 04, 2024 Filed Dec 6, 2024 21:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 135,039 | $29.39 | $3,968,796.21 |
DisclosureSEC source: 0000950170-24-134076 · ownership.xml · nonDerivative · entry 1 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 5,540,463 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $29.00 to $29.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F2 · ownership.nature: The shares are held directly by ForDyne B.V. ("ForDyne"). ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") and Forbion Growth Opportunities Fund II Cooperatief U.A. ("FGO II"). Forbion IV Management B.V. ("Forbion Management") may be deemed to have voting and dispositive power over 4,110,287 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. F3 · ownership.nature: (Continued from Footnote 2) Forbion Growth II Management B.V. ("FGO II Management"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 21:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 29,732 | $29.05 | $863,714.60 |
DisclosureSEC source: 0000950170-24-133233 · ownership.xml · nonDerivative · entry 3 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 5,675,502 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $29.00 to $29.25, inclusive. F2 · ownership.nature: The shares are held directly by ForDyne B.V. ("ForDyne"). ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") and Forbion Growth Opportunities Fund II Cooperatief U.A. ("FGO II"). Forbion IV Management B.V. ("Forbion Management") may be deemed to have voting and dispositive power over 4,249,132 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. F3 · ownership.nature: (Continued from Footnote 2) Forbion Growth II Management B.V. ("FGO II Management"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 21:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,228 | $30.37 | $37,294.36 |
DisclosureSEC source: 0000950170-24-133233 · ownership.xml · nonDerivative · entry 2 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 5,705,234 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $30.26 to $30.46, inclusive. F2 · ownership.nature: The shares are held directly by ForDyne B.V. ("ForDyne"). ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") and Forbion Growth Opportunities Fund II Cooperatief U.A. ("FGO II"). Forbion IV Management B.V. ("Forbion Management") may be deemed to have voting and dispositive power over 4,249,132 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. F3 · ownership.nature: (Continued from Footnote 2) Forbion Growth II Management B.V. ("FGO II Management"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 21:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 79,973 | $29.66 | $2,371,999.18 |
DisclosureSEC source: 0000950170-24-133233 · ownership.xml · nonDerivative · entry 1 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 5,706,462 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $29.26 to $30.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F2 · ownership.nature: The shares are held directly by ForDyne B.V. ("ForDyne"). ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") and Forbion Growth Opportunities Fund II Cooperatief U.A. ("FGO II"). Forbion IV Management B.V. ("Forbion Management") may be deemed to have voting and dispositive power over 4,249,132 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. F3 · ownership.nature: (Continued from Footnote 2) Forbion Growth II Management B.V. ("FGO II Management"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| November 14, 2024 Filed Nov 15, 2024 21:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 8,929 | $32.82 | $293,049.78 |
DisclosureSEC source: 0000950170-24-127564 · ownership.xml · nonDerivative · entry 2 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 5,786,435 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $32.50 to $33.20, inclusive. F5 · ownership.nature: The shares are held directly by ForDyne B.V. ("ForDyne"). ForDyne is jointly owned by FCF IV and Forbion Growth Opportunities Fund II Cooperatief U.A. ("FGO II"). Forbion Management may be deemed to have voting and dispositive power over 4,360,065 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. F6 · ownership.nature: (Continued from Footnote 5) Forbion Growth II Management B.V. ("FGO II Management"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 10,803 | $35.24 | $380,697.72 |
DisclosureSEC source: 0000950170-24-127564 · ownership.xml · nonDerivative · entry 1 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 62,301 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.635, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| October 21, 2024 Filed Oct 22, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 121 | $35.06 | $4,242.26 |
DisclosureSEC source: 0000950170-24-116247 · ownership.xml · nonDerivative · entry 2 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 73,104 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| October 18, 2024 Filed Oct 22, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 13,414 | $35.16 | $471,636.24 |
DisclosureSEC source: 0000950170-24-116247 · ownership.xml · nonDerivative · entry 1 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 73,225 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| October 17, 2024 Filed Oct 18, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 13,013 | $35.17 | $457,667.21 |
DisclosureSEC source: 0000950170-24-115595 · ownership.xml · nonDerivative · entry 2 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 86,639 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.64, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 23,671 | $35.35 | $836,769.85 |
DisclosureSEC source: 0000950170-24-115595 · ownership.xml · nonDerivative · entry 1 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 99,652 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| October 03, 2024 Filed Oct 7, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 5,441 | $35.13 | $191,142.33 |
DisclosureSEC source: 0000950170-24-113208 · ownership.xml · nonDerivative · entry 1 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 123,323 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| October 02, 2024 Filed Oct 3, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 21,518 | $35.38 | $761,306.84 |
DisclosureSEC source: 0000950170-24-112325 · ownership.xml · nonDerivative · entry 2 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 128,764 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.595, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 8,423 | $35.16 | $296,152.68 |
DisclosureSEC source: 0000950170-24-112325 · ownership.xml · nonDerivative · entry 1 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 150,282 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,935 | $36.02 | $69,698.70 |
DisclosureSEC source: 0000950170-24-110797 · ownership.xml · nonDerivative · entry 3 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 158,705 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $36.005 to $36.04, inclusive. F2 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 29,007 | $35.47 | $1,028,878.29 |
DisclosureSEC source: 0000950170-24-110797 · ownership.xml · nonDerivative · entry 2 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 160,640 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.995, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F2 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 32 | $35.00 | $1,120.00 |
DisclosureSEC source: 0000950170-24-110797 · ownership.xml · nonDerivative · entry 1 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 189,647 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F2 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| September 26, 2024 Filed Sep 27, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,260 | $35.29 | $44,465.40 |
DisclosureSEC source: 0000950170-24-109994 · ownership.xml · nonDerivative · entry 2 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 189,679 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.10 to $35.46, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| September 25, 2024 Filed Sep 27, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 2,357 | $35.06 | $82,636.42 |
DisclosureSEC source: 0000950170-24-109994 · ownership.xml · nonDerivative · entry 1 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 190,939 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.215, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| September 23, 2024 Filed Sep 24, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 4,610 | $36.33 | $167,481.30 |
DisclosureSEC source: 0000950170-24-109068 · ownership.xml · nonDerivative · entry 4 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 193,296 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $36.015 to $36.66, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| September 23, 2024 Filed Sep 24, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 36,221 | $35.19 | $1,274,616.99 |
DisclosureSEC source: 0000950170-24-109068 · ownership.xml · nonDerivative · entry 3 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 197,906 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.895, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| September 20, 2024 Filed Sep 24, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 471 | $37.01 | $17,431.71 |
DisclosureSEC source: 0000950170-24-109068 · ownership.xml · nonDerivative · entry 2 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 234,127 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $37.00 to $37.01, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| September 20, 2024 Filed Sep 24, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 78,940 | $36.45 | $2,877,363.00 |
DisclosureSEC source: 0000950170-24-109068 · ownership.xml · nonDerivative · entry 1 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 234,598 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $36.00 to $36.995, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| September 19, 2024 Filed Sep 20, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 50,972 | $36.41 | $1,855,890.52 |
DisclosureSEC source: 0000950170-24-108403 · ownership.xml · nonDerivative · entry 3 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 313,538 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $36.06 to $37.03, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| September 19, 2024 Filed Sep 20, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 27,767 | $35.74 | $992,392.58 |
DisclosureSEC source: 0000950170-24-108403 · ownership.xml · nonDerivative · entry 2 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 364,510 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.06 to $36.058, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| September 18, 2024 Filed Sep 20, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,554 | $35.03 | $54,436.62 |
DisclosureSEC source: 0000950170-24-108403 · ownership.xml · nonDerivative · entry 1 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 392,277 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| September 17, 2024 Filed Sep 18, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 3,272 | $35.13 | $114,945.36 |
DisclosureSEC source: 0000950170-24-107768 · ownership.xml · nonDerivative · entry 2 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 393,831 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.22, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.